Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease

The number of patients with nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) is increasing globally and is raising serious concerns regarding the increasing medical and economic burden incurred for their treatment. The progression of NASH to more severe conditions such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamata, Shotaro, Honda, Akihiro, Ishii, Isao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452531/
https://www.ncbi.nlm.nih.gov/pubmed/37627329
http://dx.doi.org/10.3390/biom13081264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452531/
https://www.ncbi.nlm.nih.gov/pubmed/37627329
http://dx.doi.org/10.3390/biom13081264

Ejemplares similares